Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Niu · SciRah

Researcher profile · Semantic Scholar

J. Niu

Share profile

J. Niu — researcher profile on SciRah

h-index: 18
Works: 88
Citations: 2,653

Most-cited papers

PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma
M. Migden, D. Rischin, C. Schmults, A. Guminski +33 more
2018New England Journal of Medicine1,193 citations Open access
Semantic Scholar
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer.
J. Niu, C. Maurice-Dror, D. Lee, D.-W. Kim +15 more
2021Annals of Oncology240 citations Open access
Semantic Scholar
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunil Kakadia, N. Yarlagadda, Ramez Awad, M. Kundranda +6 more
2018OncoTargets and Therapy230 citations Open access
Semantic Scholar
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
M. Kundranda, J. Niu
2015Drug Design, Development and Therapy211 citations Open access
Semantic Scholar
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
G. Weiss, J. Waypa, Lisa Blaydorn, J. Coats +6 more
2017British Journal of Cancer125 citations Open access
Semantic Scholar
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors
A. Mansfield, D. Hong, C. Hann, A. Farago +16 more
2021npj Precision Oncology62 citations Open access
Semantic Scholar
Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma
M. Milhem, R. Gonzales, T. Medina, J. Kirkwood +11 more
2018Clinical Trials54 citations
Semantic Scholar
Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
J. Niu, G. Andres, K. Kramer, M. Kundranda +6 more
2015OncoTargets and Therapy47 citations Open access
Semantic Scholar
Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors
A. Chambers, M. Kundranda, Santosh Rao, Fade Mahmoud +1 more
2021Current Oncology Reports39 citations
Semantic Scholar
Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review.
J. Niu, M. Mims
2012Journal of Clinical Oncology35 citations
Semantic Scholar
1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
M. Ahn, J. Niu, D.-W. Kim, D. Rasco +11 more
2020Annals of Oncology30 citations Open access
Semantic Scholar
The effect of 5-Aminolaevulinic Acid Photodynamic Therapy versus CO2 laser in the Treatment of Cervical Low-grade Squamous Intraepithelial Lesions with High-Risk HPV Infection: a non-randomized, controlled pilot study.
J. Niu, Mengxing Cheng, Zu-Bei Hong, Jiayan Ling +3 more
2021Photodiagnosis and Photodynamic Therapy27 citations
Semantic Scholar
O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab
M. Milhem, Y. Zakharia, D. Davar, E. Buchbinder +18 more
2020Journal of Immunotherapy for Cancer26 citations Open access
Semantic Scholar
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.
A. Mansfield, D. Hong, C. Hann, A. Farago +16 more
2020Journal of Clinical Oncology25 citations
Semantic Scholar
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma
M. Milhem, Y. Zakharia, D. Davar, E. Buchbinder +20 more
202025 citations Open access
Semantic Scholar
Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE).
M. Milhem, A. Vanderwalde, T. Bowles, J. Sacco +15 more
2022Journal of Clinical Oncology20 citations
Semantic Scholar
1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
J. Niu, A. Nagrial, M. Voskoboynik, H. Chung +11 more
202020 citations Open access
Semantic Scholar
An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.
M. Middleton, F. Aroldi, J. Sacco, M. Milhem +16 more
202019 citations
Semantic Scholar
Cyclophosphamide-Induced Severe Acute Hyponatremic Encephalopathy in Patients with Breast Cancer: Report of Two Cases
M. Baker, M. Markman, J. Niu
2014Case Reports in Oncology17 citations Open access
Semantic Scholar
Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of the literature
Jie Cheng, J. Niu, You Wang, Chuan Wang +5 more
2019Journal of Obstetrics and Gynaecology Research15 citations
Semantic Scholar
Clinical features and prognosis-associated factors of non-small cell lung cancer exhibiting symptoms of bone metastasis at the time of diagnosis.
Yi-Fu He, Hui-Qin Luo, W. Wang, Jian Chen +11 more
2015Oncology Letters13 citations Open access
Semantic Scholar
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
B. Cho, K. Yoh, R. Perets, A. Nagrial +14 more
2021Lung Cancer10 citations Open access
Semantic Scholar
422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts
M. Middleton, F. Aroldi, J. Sacco, M. Milhem +18 more
202010 citations Open access
Semantic Scholar
HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report.
J. Niu, D. Gelbspan, David J Weitz, M. Markman +1 more
2014Journal of Gastrointestinal Oncology10 citations
Semantic Scholar
Change of HER2 status in metastatic esophageal adenocarcinoma: heterogeneity of the disease? Case report and review of literature.
J. Niu, J. Weber, D. Gelbspan
2012Journal of Gastrointestinal Oncology10 citations
Semantic Scholar
A phase I trial evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers.
Colette J. Shen, J. Frakes, J. Niu, A. Rosenberg +5 more
20219 citations
Semantic Scholar
Phase 1 study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Final efficacy and safety data.
T. Owonikoko, K. Papadopoulos, M. Johnson, M. Martín +15 more
20189 citations
Semantic Scholar
First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers.
A. Ho, M. Posner, J. Niu, S. Fu +16 more
20218 citations
Semantic Scholar
Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Hardy Niu, Junle Zhou, Harvinder Maan, M. Markman +1 more
2017Case Reports in Oncology8 citations Open access
Semantic Scholar
Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.
J. Niu, H. Kaufman, G. Kichenadasse, A. Haydon +8 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
Safety and Efficacy of RP1 + Nivolumab in Patients with Non-Melanoma Skin Cancer of the Head and Neck: Results From IGNYTE Phase 1/2 Multi-Cohort Clinical Trial
J. Niu, M. Milhem, A. Vanderwalde, B. Chmielowski +9 more
2022International Journal of Radiation Oncology, Biology, Physics7 citations
Semantic Scholar
Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.
Colette J. Shen, J. Frakes, J. Niu, J. Weiss +7 more
2023Journal of Clinical Oncology6 citations
Semantic Scholar
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC
M. Negrao, V. Papadimitrakopoulou, A. C. Price, A. Tam +13 more
2022JTO Clinical and Research Reports6 citations Open access
Semantic Scholar
950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma
J. Kirkwood, Y. Zakharia, D. Davar, E. Buchbinder +20 more
2021Journal for ImmunoTherapy of Cancer6 citations Open access
Semantic Scholar
Abstract CT032: CMP-001 demonstrates improved response in noninflamed anti-PD-1 refractory melanoma and response is associated with serum CXCL10
J. Luke, R. Bao, J. Kirkwood, Y. Zakharia +19 more
2021Clinical Trials6 citations
Semantic Scholar
684 NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers: results from an ongoing dose escalation phase I trial (Study 1100)
Colette J. Shen, J. Frakes, J. Niu, J. Weiss +9 more
2022Regular and Young Investigator Award Abstracts5 citations Open access
Semantic Scholar
A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies.
A. Haydon, G. Kichenadasse, J. Kirkwood, Howard Kaufman +9 more
2021Journal of Clinical Oncology5 citations
Semantic Scholar
436PDPreliminary safety and efficacy of rovalpituzumab tesirine in patients with delta-like protein 3-expressing advanced solid tumors
R. Aggarwal, A. Mansfield, H. Beltran, A. Farago +16 more
20175 citations Open access
Semantic Scholar
Effect of Apatinib on Serum CD4+CD25+ T cells, NK Cells, and T Cells Subgroup in Malignant Tumor
Hui-Qin Luo, Yi-Fu He, Wen-ju Chen, Ying Yan +6 more
2019Technology in Cancer Research and Treatment4 citations Open access
Semantic Scholar
Lung Adenocarcinoma Presenting with WDHA Syndrome and Marie-Bamberger Syndrome: A Case Report
J. Niu, D. Gelbspan, Lanceford M. Chong, S. Birdsall +2 more
20134 citations
Semantic Scholar
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With PD-1/PD-L1 Blockade−Resistant Advanced Non−Small Cell Lung Cancer
M. Negrao, V. Papadimitrakopoulou, A. C. Price, A. Tam +13 more
2022JTO Clinical and Research Reports3 citations Open access
Semantic Scholar
Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation
K. Harrington, F. Aroldi, J. Sacco, M. Milhem +23 more
2021Immunology3 citations
Semantic Scholar
Systemic therapy in patients with NSCLC with brain metastasis: the emerging role of immunotherapy
J. Niu, Junle Zhou, S. Lindebak, Fade Mahmoud
2018Neuroimmunology and Neuroinflammation3 citations Open access
Semantic Scholar
Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.
J. Niu, M. Kundranda, M. Markman, J. Farley
2017European Journal of Gynaecological Oncology3 citations
Semantic Scholar
Metastatic Breast Cancer with Extensive Osseous Metastasis Presenting with Symptomatic Immune Thrombocytopenic Purpura and Anemia: A Case Report and Review of the Literature
J. Niu, Teresa A Goldin, M. Markman, M. Kundranda
2015Case Reports in Oncology3 citations Open access
Semantic Scholar
Abstract CT153: TiTAN: a phase 1 study of GEN-011, a neoantigen-targeted peripheral blood-derived T cell therapy with broad neoantigen targeting
M. Gillison, J. Niu, D. Olson, M. Stein +14 more
2022Cancer Research2 citations
Semantic Scholar
BRAF mutation classes and co-occurring mutations in NSCLC.
J. Niu, Cynthia A. Flannery, D. Hall, J. Hoag +6 more
2022Journal of Clinical Oncology2 citations
Semantic Scholar
611 Biodistribution and shedding analysis following treatment with RP1 oncolytic immunotherapy in the skin cancer patients from the IGNYTE clinical trial
M. Milhem, A. Vanderwalde, T. Bowles, J. Sacco +19 more
2022Regular and Young Investigator Award Abstracts2 citations
Semantic Scholar
NBTXR3 Activated by Radiotherapy in Combination With Nivolumab or Pembrolizumab in Patients With Advanced Cancers: A Phase I Trial.
C. Shen, J. Frakes, J. Niu, A. Rosenberg +5 more
2021International Journal of Radiation Oncology, Biology, Physics2 citations
Semantic Scholar
906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
A. Hansen, C. Gomez-Roca, M. Lolkema, L. Verlingue +15 more
2021Annals of Oncology2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Milhem×10
Invite
M. Milhem — researcher profile on SciRah
J. Kirkwood×7
Invite
J. Kirkwood — researcher profile on SciRah
A. Krieg×7
Invite
A. Krieg — researcher profile on SciRah
M. Kundranda×6
Invite
M. Kundranda — researcher profile on SciRah

×6

Invite

M. Markman — researcher profile on SciRah

Invite

T. Medina — researcher profile on SciRah

E. Buchbinder×5

Invite

E. Buchbinder — researcher profile on SciRah

Invite

M. Shaheen — researcher profile on SciRah

Invite

K. Margolin — researcher profile on SciRah

Invite

J. Luke — researcher profile on SciRah

Invite

D. Mauro — researcher profile on SciRah

Invite

A. Ribas — researcher profile on SciRah